Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Breast Cancer

 

Premenopausal Early Assessment; ER+, HER2-, FLT (7536a)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Postmenopausal Early Assessment; ER+, HER2-, FLT (7536b)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)
Phase I-II Study of HER2 Vaccination with poly(I) poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT01355393

I-SPY2 Trial (7518)
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)

Investigator: Larissa Korde;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01042379

Early Assessment Challenge Grant (7043)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy

Investigator: David Mankoff, M.D., PhD ;   Conditions: Breast Cancer;    Status: Recruiting

Whole Breast Irradiation with Hypofractionation versus standard Whole Breast Irradiation (RTOG 1005)
A Phase III clinical trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent boost versus standard Whole Breast Irradiation plus sequential boost for early-stage breast cancer.

Investigator: George Laramore, MD;   Conditions: Breast cancer;    Status: Recruiting;   Study ID: NCT01349322

Psychoeducation for Spouses of Women With Breast Cancer
Psychoeducation for Spouses of Women With Breast Cancer (Helping Her Heal)

Investigator: ;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01723943

SPORE Project 3 (7587)
Quantitative Dynamic PET and MRI and Breast Cancer Therapy

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01931709

Acupuncture vs. Sham Acupuncture for AI-induced Arthralgias (S1200)
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01535066

Screening Tomosynthesis and Automated Breast Ultrasound Research (STAR-8159)
Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts

Investigator: Constance Lehman, MD ;   Conditions: Women with dense breasts and risk of breast cancer (see below).;    Status: Recruiting;   Study ID: NCT02042456

Kadcyla + Pertuzumab vs. Herceptin + Pertuzumab + Taxane for HER2-positive Breast Cancer
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus A Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy In Patients With Operable Her2 Positive Primary Breast Cancer

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01966471

Hormone Therapy w/o Everolimus for Breast Cancer (SWOG 1207)
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01674140